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(Author list continued on next page)AbstractA combination of genetic and functional approaches has identified three independent breast cancer risk loci at 2q35. A recent fine-scale
mapping analysis to refine these associations resulted in 1 (signal 1), 5 (signal 2), and 42 (signal 3) credible causal variants at these loci.
We used publicly available in silico DNase I and ChIP-seq data with in vitro reporter gene and CRISPR assays to annotate signals 2 and 3.
We identified putative regulatory elements that enhanced cell-type-specific transcription from the IGFBP5 promoter at both signals (30-
to 40-fold increased expression by the putative regulatory element at signal 2, 2- to 3-fold by the putative regulatory element at signal 3).
We further identified one of the five credible causal variants at signal 2, a 1.4 kb deletion (esv3594306), as the likely causal variant; the
deletion allele of this variant was associated with an average additional increase in IGFBP5 expression of 1.3-fold (MCF-7) and 2.2-fold
(T-47D). We propose a model in which the deletion allele of esv3594306 juxtaposes two transcription factor binding regions (annotated
by estrogen receptor alpha ChIP-seq peaks) to generate a single extended regulatory element. This regulatory element increases cell-type-
specific expression of the tumor suppressor gene IGFBP5 and, thereby, reduces risk of estrogen receptor-positive breast cancer (odds ratio
¼ 0.77, 95% CI 0.74–0.81, p ¼ 3.1 3 1031).Introduction
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of causal variants (as opposed to correlative variants), the
targets of these functional variants (the genes or non-cod-
ing RNAs that mediate the associations observed in
genome-wide association studies) and an understanding
of the disease causal cell types and processes.1 Genome-
wide association studies of breast cancer coupled with
large-scale replication and fine-mapping studies have led
to the identification of approximately 200 breast cancer
risk loci;3,5–9 two of these loci, annotated by
rs1338704210 and rs16857609,5 map to a gene desert at
chromosome 2q35. Fine-scale mapping, combined with
in silico annotation, reporter gene assays, and allele-specific
qRT-PCR led to the identification of a putative causal
variant (rs4442975) at the rs13387042 locus.11,12
rs4442975, which is highly correlated with the tag SNP
rs13387042 (r2 ¼ 0.92, D0 ¼ 0.96), maps to a consensus
binding site for the transcription factor (TF) forkhead box
A1 (FOXA1 [MIM: 602294]) with the alternative T-allele
promoting binding of FOXA1.11,12 To date, no putative
causal variant at the rs16857609 locus has been reported.
Chromatin interaction methods implicate IGFBP5 (MIM:
146734) as the target gene at both loci11–13 and for the
rs13387042 locus, eQTL analyses demonstrated associa-
tion of the protective T-allele with slightly increased
IGFBP5 levels in normal breast tissue11 and estrogen recep-
tor-positive (ERþ) breast cancers.12
Taking a functional approach based on chromosome
conformation capture (3C) assays that were anchored at
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a putative regulatory element centered on a structural
variant (SV; esv3594306) that maps approximately 400
kb telomeric to IGFBP5.14 Allele-specific expression ana-
lyses and follow-up genotyping identified 14 highly corre-
lated variants (all r2 > 0.8 with the top SNP, rs34005590)
associated with breast cancer risk, which represent a third
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The AmericIn this analysis we report fine-scale mapping of the 2q35
region in European and Asian individuals with breast
cancer and control subjects from the Breast Cancer Associ-
ation Consortium. We confirm three independent, high-
confidence signals at 2q35 annotated by rs13387042
(signal 1), rs138522813 (signal 2), and rs16857609 (signal
3). We carry out functional annotation of credible variants
at signals 2 and 3 and implicate the deletion variant
(esv3594306) at signal 2 as causally associated with
increased IGFBP5 expression and reduced breast cancer
risk.
Material and methods
Fine-scale mapping of the 2q35 breast cancer risk locus
Fine-scale mapping of the 2q35 breast cancer risk locus was carried
out as part of a large collaborative project; full details have been
published.3 Briefly, for the current analysis we accessed data
from 94,391 individuals with invasive breast cancer and 83,477 in-
dividuals of European ancestry and 12,481 individuals with inva-
sive breast cancer and 12,758 control subjects of Asian ancestry
from 87 studies participating in the Breast Cancer Association
Consortium. All participating studies were approved by their
appropriate ethics review board and all subjects provided
informed consent.
Directly genotyped or imputed (info score> 0.8) calls for 10,314
SNPs mapping to a 1.4 Mb region at 2q35 (chr2:217,405,832–
218,796,508; GRCh37/hg19) were available for analysis. At this
threshold, the proportions of common variants (MAF R 0.05),
low-frequency variants (0.01 % MAF < 0.05), and rare variants
(0.001 % MAF < 0.01)3 that could be analyzed were 89.7%,
68.5%, and 3.6%, respectively, for OncoArray and 64.2%, 40.5%,
and 0.8%, respectively, for iCOGS. Analysis of the association be-
tween each SNP and risk of breast cancer was performed using un-
conditional logistic regression assuming a log-additive genetic
model, adjusted for study and up to 15 ancestry-informative prin-
cipal components. p values were calculated using Wald tests. For-
ward stepwise logistic regression was used to explore whether
additional loci in the fine-mapping region were independently
associated with breast cancer risk. We carried out stratified ana-
lyses to determine whether each of the independent associationsesearchMalaysia, Subang Jaya, Selangor 47500, Malaysia; 168Department of
laysia; 169Department of Epidemiology, Mailman School of Public Health,
Biology and Genetics, The Ohio State University, Columbus, OH 43210,
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dam 3015 GD, the Netherlands; 176Biostatistics and Computational Biology
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differed according to estrogen receptor (ER) status; heterogeneity
between stratum-specific estimates was assessed using Cochran’s
Q-test. All statistical analyses were carried out using R version
3.6.1.
In silico annotation of credible variants
Credible variants at each of the three independent signals were
aligned with DNase I and ChIP-seq data (P300 [EP300 (MIM:
602700)], H3K27Ac, H3K4me1, FOXA1, GATA3 [MIM: 131320],
ERa [ESR1 (MIM: 133430)]) generated in T-47D and MCF-7 breast
cancer cells15–17 (Table S1).
Cloning of reporter assay constructs
All reporter assay plasmids were derived using the pGL4 reporter
vector (Promega). Reporter vectors were constructed using a restric-
tion digest-based cloning approach. The IGFBP5 promoter and
putative regulatory element regions (containing WT alleles) were
synthesized as gBlocks (Integrated DNA Technologies, full details
inTable S2).Double restrictiondigestsofplasmidorgBlockwereper-
formed using BglII and XhoI (for IGFBP5 promoter) or SalI and
BamHI (for putative regulatory element regions) according to the
manufacturer’s instructions (NewEnglandBiolabs [NEB]). Ligations
were performed in a 3:1 insert:vector ratio using T4 DNA ligase
(NEB), according to manufacturer’s instructions. Correct cloning
was validated by Sanger sequencing using a commercially available
service (Eurofins Genomics). Alternative (ALT) alleles of each
variant were introduced into reporter vectors using QuikChange
Lightning Site-directed Mutagenesis kit (Agilent Technologies), ac-
cording to the manufacturer’s instructions. Accurate mutagenesis
was confirmed by Sanger sequencing (Eurofins Genomics). All re-
porter gene constructs are shown in Figure S1.
Cell Culture
T-47D cells were grown in RPMI (GIBCO) supplemented with 10%
FBS (GIBCO), 10 mg/mL human insulin (Sigma), and 100 U/mL
penicillin with 100 mg/mL streptomycin (Sigma). HCT116 cells
were grown in RPMI supplemented with 10% FBS, 100 U/mL peni-
cillin, and 100 mg/mL streptomycin. HepG2 cells were grown in
EMEM (LGC Standards-ATCC) supplemented with 10% FBS and
100 U/mL penicillin with 100 mg/mL streptomycin. MCF-7 cells
(including derivative Cas9-expressing cell lines) and 293T cells
were grown in DMEM (GIBCO) supplemented with 10% FBS
and 100 U/mL penicillin with 100 mg/mL streptomycin. All cell
lines were routinely short tandem repeat (STR)-typed and tested
for mycoplasma contamination.
Reporter assays
Reporter assays were performed in T-47D, MCF-7, 293T, HCT116,
and HepG2 cell lines. Antibiotics were removed from standard
growth media 24 h before transfection to improve viability. For as-
says performed under standard conditions, approximately 16,000
cells were seeded per well of a 96-well plate for T-47D, MCF-7, and
HepG2, and approximately 8,000 cells were seeded per well of a
96-well plate for 293T and HCT116. Transfection was performed
upon reaching 70% confluency (~24 h after cell seeding). For as-
says performed after 17b-estradiol treatment, cells were first hor-
mone starved for 48 h. Approximately 10,000 cells (T-47D) and
8,000 cells (MCF-7) were seeded, per well of a 96-well plate, in
standard growth media and cultured for 24 h. The media was
then replaced with phenol red-free media (GIBCO) supplemented
with 10% charcoal-stripped FBS (GIBCO), 100 U/mL penicillin1194 The American Journal of Human Genetics 108, 1190–1203, Julywith 100 mg/mL streptomycin, 10 nM fulvestrant (I4409, Sigma),
and 10 mg/mL human insulin (T-47D only). After 48 h, growthme-
dia was replaced with phenol red-free media supplemented with
10% charcoal-stripped FBS, 10 mg/mL human insulin (T-47D
only), with the addition of either (1) 10 nM 17b-estradiol
(E2758, Sigma) or (2) vehicle (ethanol). Transfection was per-
formed upon reaching 80% confluency (6 h after 17b-estradiol
or vehicle treatment).
Transfection was performed using X-tremeGENEHPDNA trans-
fection reagent (Roche). Equimolar amounts of the test pGL4-
based firefly luciferase vector and pRL-TK renilla luciferase control
(Promega) were combined in a 3:1 reagent:DNA ratio in OptiMEM
(Fisher Scientific). After a 30 min incubation at room temperature,
10 mL transfection mixture was added per well. Each biological
replicate was performed in technical triplicates with non-trans-
fected, mock-transfected, and pEGFP-transfected controls (Takara
Bio Inc). Cells were screened for luciferase activity 48 h after trans-
fection using the Dual-Glo Luciferase Assay System (Promega) ac-
cording to the manufacturer’s instructions.
Confirmatory genotyping and sequencing of putative
regulatory element 2 (PRE2)
Four of the five variants mapping to PRE2 (rs72951831,
rs199804270, rs138522813, and esv3594306) are highly correlated
based on 1000 Genomes data (1KGP), with the ALT alleles of
rs72951831, rs199804270, and rs138522813 all predicted to occur
in combination with the ALT (deletion) allele of esv3594306
(esv3594306: rs72951831 r2 ¼ 1.0, D0 ¼ 1.0; esv3594306:
rs199804270 r2 ¼ 0.95, D0 ¼ 1.0; esv3594306: rs138522813 r2 ¼
1.0, D0 ¼ 1.0) . However, rs572022984 (hg19, chr2:217955897)
theoretically maps within the esv3594306 deleted region
(chr2:217,955,891–217,957,273) casting doubt on whether the
(imputed) rs572022984-del allele could occur in combination
with the esv3594306 deletion allele. To clarify this, we genotyped
all five variants in 300 randomly selected women participating in
the Generations Study18 using MassARRAY (Agena Bioscience;
full details of primers available on request). The number of carriers
of the alternative (A>-) allele at rs572022984 (MAF ¼ 0.035) was
0 (expected number ¼ 21; p ¼ 0.00002). To confirm our genotyp-
ing, we carried out Sanger sequencing (Eurofins) of a 2.4 kb region
spanning (chr2:217,955,586–217,958,000) in two individualswho
were heterozygous at the linked PRE2 SNP rs138522813. Primers
were: forward 50-CGCTTCCCCTTCATCACTTG-30 and, reverse
50-TCTCTCAGGCCAAGTCACAG-30. Sequencing confirmed the
presence of REF and ALT alleles of esv3594306, rs72951831, and
rs199804270 (rs138522813maps just outside the amplified region)
but only REF alleles at rs572022984; on this basis we excluded
rs572022984 from further analyses.
Cloning of guides for CRISPR-based enhancer
perturbation
Guides were designed using the online design tool CHOPCHOP
(http://chopchop.cbu.uib.no). Guides were selected based on their
proximity to variants of interest and specificity scores. Full details
are provided in Table S3. Cloning was performed essentially as
described in Ran et al.19 Briefly, guides were produced as two com-
plementary oligonucleotides with overhangs to facilitate cloning.
Oligos were annealed with T4 Polynucleotide Kinase (NEB). The
expression vector pKLV-U6gRNA(BbsI)-PGKpuro2ABFP (Addgene
#50946) was digested using BbsI (NEB), and ligation performed us-
ing T4 DNA ligase (NEB). Cloning was validated by sequencing
(Eurofins Genomics).1, 2021
CRISPR-based enhancer perturbation
All CRISPR cell lines were derived from a parental MCF-7 cell line.
Expression of each dCas9 construct was introduced by transduction
with a specific Cas9-expressing lentivirus: pGH125_dCas9-Blast
(Addgene #85417) for dCas9; pHR-SFFV-KRAB-dCas9-P2A-mCherry
(Addgene #60954) for dCas9-KRAB; Lenti-hEF1-BLAST-dCas9-VPR
(Dharmacon, CAS11916) for dCas9-VPR. Successfully transduced
cells were then selected for by mCherry expression (dCas9-KRAB)
or treatment with 10 mg/mL blasticidin (dCas9 and dCas9-VPR;
GIBCO). Cells were then seeded into 24-well plates at a density of
50,000 cells per well. 100 mL of sgRNA lentivirus was added. After
24 h, media was replaced and after 48 h cells were lysed using the
Cells-to-Ct kit (Life Technologies) for subsequent gene expression
analysis by RT-PCR.
Real-time PCR
Real-time PCR analysis of gene expression in cDNA samples was
performed using Taqman probes (Life Technologies) for IGFPB2
(MIM: 146731), IGFBP5, and RPL37A (MIM: 613314) normalized
to the housekeeping gene GAPDH (ThermoFisher; IGFBP2: Hs
01040719_m1, IGFBP5: Hs00181213_m1, RPL37A: Hs011023
45_m1, GAPDH: Hs03929097_g1). Reactions of 5 mL were estab-
lished using Taqman Universal Master Mix II, without
UNG (Applied Biosystems) according to the manufacturer’s
instructions.
Statistical analysis of reporter gene assays and CRISPR-
based enhancer perturbation
Firefly luciferase activity was internally normalized to renilla
luciferase activity, and each test condition normalized to the
‘‘IGFBP5 promoter-alone’’ (IGFBP5-PROM) construct. Setting
IGFBP5-PROM to 1.0, for each putative enhancer-containing re-
porter gene construct we used t tests to test (1) H0: the mean
dual luciferase ratio does not differ from 1.0 and (2) H0: the
ALT construct does not differ from the REF construct. To compare
mean dual luciferase ratios for each combination of SNP and SV
at PRE2, we used three-way analysis of variance adjusting each
variant for all other variants. To account for multiple testing,
we used a Bonferroni corrected p value of 0.0056 (individual con-
structs, Figure 2; 9 tests) and 0.017 (PRE2 combinations, Figure 3;
3 tests).
Relative gene expressionwas calculated using theDDCTmethod.
For the negative control sgRNAs (TAG-1 and TAG-2), we used t
tests to test H0: the relative gene expression does not differ from
1.0. To maximize the power of subsequent analyses, we then com-
bined the negative control data and for each of the other sgRNAs
we tested H0: relative gene expression does not differ from the
combined negative control relative gene expression. To account
for multiple testing, we used a Bonferroni corrected p value of
0.017 (PROM sgRNAs Figures 4A; 3 tests per gene) and 0.0056
(PRE2 sgRNAs, Figures 4B and 4C; 9 tests per gene).
Ethics approval and consent to participate
All participating studies were approved by their appropriate ethics
review board and all subjects provided informed consent.Results
Fine-scale mapping of a 1.4 Mb region at 2q35
(chr2:217,407,297–218,770,424; GRCh37/hg19; Figure 1A)The Americin combineddata fromup to109,900 individualswithbreast
cancer and 88,937 control subjects of European Ancestry
from the Breast Cancer Association Consortium confirmed
the presence of three independent signals (p < 5 3 108;
Figure S2) at this region.3 After conditioning on the top
SNPat eachof these three signals (signal 1, rs4442975; signal
2, rs138522813; signal 3, rs5838651), there were no addi-
tional high-confidence signals (defined as signals for which
p < 1 3 106).3 Defining credible causal variants at each
signal asvariantswithconditionalpvalueswithin twoorders
of magnitude of the index variant there were 1, 5, and 42
crediblecausalvariants at PRE1,PRE2, andPRE3, respectively
(Table S4). Fine-scale mapping of this region in women of
Asian Ancestry (12,481 affected individuals and 12,758 con-
trol subjects) did not identify anypopulation-specific signals
(all associationsp>53108; Figure S3).Noneof the credible
causal variants at signal 2 was present in women of Asian
ancestry. The published causal variant at signal 1
(rs4442975) and all of the signal 3 credible causal variants
(Table S5) were nominally associated with breast cancer risk
in Asian women (p < 0.05). At signal 3, the index variants
differ between Europeans and Asians (rs5838651 and
2:218265091:G:<INS:ME:ALU>:218265367, respectively)
but none of the European credible causal variants could be
excluded on the basis of the Asian data.
The T-allele of rs4442975 was associated with reduced
breast cancer risk (per allele OR ¼ 0.88, 95% CI 0.87–
0.89, p ¼ 1.3 3 1075 and OR ¼ 0.94, 95% CI 0.89–1.00,
p ¼ 0.04 in European and Asian women, respectively)
and the delG-allele of rs5838651 was associated with
increased risk (per allele OR ¼ 1.07, 95% CI 1.05–1.08,
p ¼ 1.5 3 1016 and OR ¼ 1.07, 95% CI 1.03–1.11,
p ¼ 0.0008 in European and Asian women, respectively;
Table 1). The delT-allele of rs138522813 was associated
with reduced risk (carrier OR ¼ 0.80 95% CI 0.77–0.83,
p ¼ 5.5 3 1032). Stratifying by ER status, the signal 1
(rs4442975) and signal 2 (rs138522813) SNPs were more
strongly associated with ERþ disease; for the signal 3 SNP
(rs5838651), there was no evidence that the ORs differed
by ER status (Table S6).
Prioritization of credible variants for functional
follow up
Fachal and colleagues3 used a Bayesian approach (PAIN-
TOR) that combines genetic association, linkage disequi-
librium, and enriched genomic features to determine
variants with high posterior probabilities of being causal
(Table S4).20 rs4442975, the only credible causal variant
at signal 1 (posterior probability ¼ 0.84), has previously
been proposed to have a functional effect on breast can-
cer risk.11,12 Four of the five variants at signal 2 had
posterior probabilities R 0.20 (combined posterior prob-
ability 0.997); none of the variants at signal 3 had pos-
terior probabilities > 0.15. To further prioritize putative
causal variants at signals 2 and 3, we aligned the 47
credible variants at these signals with markers of open




Figure 1. 2q35 breast cancer risk locus
(A) Fine-scale mapping at 2q35 identified three high-confidence (p < 13 106) signals annotated by rs4442975 (signal 1), rs138522813
(signal 2), and rs5838651 (signal 3). The putative target gene (IGFBP5) maps 360 kb, 399 kb, and 703 kb from signals 1, 2, and 3, respec-
tively. All coordinates are based on GRCh37/hg19.
(B) Putative regulatory element 2 (PRE2; chr2:217,955,458–217,957,767) at signal 2 colocalizes with four highly correlated variants: three
single-nucleotide polymorphisms (SNPs; rs572022984, rs199804270, and rs72951831) and a 1.4 kb insertion/deletion variant
(esv3594306; indicated by a black bar). A fourth SNP (rs138522813)maps outside the proposed boundaries of PRE2. Regions of open chro-
matin (DNase I) andChIP-seq binding peaks for transcription factors are shown as gray bars where the shade of gray indicates the strength
of the ChIP-seq peak (light gray, weak binding; dark gray, strong binding). Also shown (yellow bars) are the coordinates of three reporter
gene constructs (PRE2A, PRE2B, and PRE2DEL) and the locations of sequences targeted by nine small guide (sg)RNAs.
(C) PRE3 (chr2:218,305,944–218,306,443) indicated by a blue bar colocalizes with two SNPs (rs12694417 and rs12988242). Regions of
open chromatin and ChIP-seq binding peaks are as in (B).enhancers (H3K27Ac, H3K4me1), and breast-relevant
TFs (FOXA1, GATA3, ERa) generated in T-47D and
MCF-7 breast cancer cells15–17 (Table S4). Consistent
with the PAINTOR posterior probabilities, four variants
at signal 2 colocalized with at least one of these fea-
tures. In addition, we identified two variants at signal
3 that colocalized with one of these features. These
six variants were prioritized for further functional
annotation.
Reporter gene assays of prioritized variants
For SNPs, we generated reference (REF) and alternative
(ALT) constructs in which the putative regulatory element,
defined in the first instance as a 500 to 700 bp region
centered on the SNP or SNP pair (PRE2A rs572022984;1196 The American Journal of Human Genetics 108, 1190–1203, JulyPRE2B rs199804270 and rs72951831; PRE3 rs12694417
and rs12988242, Table S2; Figures 1B and 1C), was cloned
upstreamof a luciferase reporter gene, driven by the IGFBP5
promoter (Figure S1). For the structural variant esv3594306,
which is defined by the presence (REF) or absence (ALT) of a
1.4 kb region (chr2:217,955,891–217,957,273; GRCh37/
hg19), we generated separate REF constructs for PRE2A
and PRE2B and a single ALT construct in which the centro-
meric sequences at PRE2Awere juxtaposed to the telomeric
sequences at PRE2B with the intervening 1.4 kb deleted
(Figure 1B). Comparing the REF construct at each region
with the IGFBP5promoter construct (IGFBP5-PROM), there
was evidence that two of the putative regulatory elements
(PRE2B and PRE3) enhanced transcription from the IGFBP5


















































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Luciferase reporter assays following transient trans-
fection of PRE2 and PRE3, REF and ALT constructs, into MCF-7,
T-47D, and HepG2 cells
The PRE containing the reference (REF) allele at each SNP was
cloned downstream of the IGFBP5 promoter to generate reference
(REF) luciferase constructs. Alternative (ALT) alleles were gener-
ated by site-directed mutagenesis. Coordinates of the PREs are
given in Table S2, diagrams are in Figure S1. Error bars denote stan-
dard deviations based on three independent experiments each
done in triplicate. p values were determined by t tests and a Bon-
ferroni correction was applied to account for multiple testing.
Comparing each PRE containing construct to IGFBP5-PROM, *p
< 0.0056, **p % 0.00056; comparing ALT to REF constructs #p <
0.0056.
The Americstrong enhancer activity (PRE2B-REF/REF: fold change
[FC] ¼ 27.9, p ¼ 0.004 and FC ¼ 28.7, p ¼ 0.0005; PRE2-
DEL-ALT/ALT: FC ¼ 50.5, p ¼ 0.004 and FC ¼ 44.9, p ¼
0.03 inMCF-7 and T-47D, respectively). For PRE3 the activ-
ity was more modest and only significant (p < 0.0056; Ma-
terial and methods) for the ALT allele in T-47D (PRE3-REF/
REF: FC ¼ 1.8, p ¼ 0.03 and FC ¼ 2.9, p ¼ 0.006; PRE3-
ALT/ALT FC ¼ 2.2, p ¼ 0.008 and FC ¼ 2.8, p ¼ 0.003 in
MCF-7 and T-47D, respectively; Figure 2). To test these con-
structs for cell type specificity, we used HepG2 (hepatocyte
carcinoma), 293T (embryonic kidney), and HCT116 (colo-
rectal carcinoma) cells; the only construct that influenced
transcription from the IGFBP5 promoter in these non-
breast cells was PRE2DEL-ALT/ALT in 293T cells and with
an effect size that was an order of magnitude lower (FC ¼
1.9, p ¼ 0.002; Figure S4) compared to the breast cancer
cell lines (FC > 40; Figure 2). Comparing ALT constructs
with REF constructs, only the PRE2 region showed a signif-
icant difference between alleles, with the (protective) PRE2-
DEL-ALT/ALT allele being associated with greater activity
than PRE2B-REF/REF allele (MCF-7 FC ¼ 1.8, p ¼ 0.003;
T-47D FC ¼ 1.6, p ¼ 0.09; Figure 2). Repeating these assays
in cells that were grown in the presence of low-dose estra-
diol did not alter these results; both PRE2B and PRE3 were
responsive to low-dose estradiol (Figures S5A and S5B) but
only PRE2 showed a difference between alleles, with the
protective PRE2DEL-ALT/ALT allele once again being
associated with significantly greater activity than thean Journal of Human Genetics 108, 1190–1203, July 1, 2021 1197
A B Figure 3. Luciferase reporter assays
following transient transfection of con-
structs with allelic variants at PRE2B and
PRE2DEL into MCF-7 and T-47D cells
Reporter gene constructs with all possible
combinations of rs199804270 and rs7295
1831 and esv3594306 were generated by
site-directed mutagenesis of the naturally
occurring haplotypes at PRE2B and PRE2-
DEL (Material and methods) into MCF-7
(A) and T-47D (B) cells. Coordinates of the
PREs are given in Table S2, diagrams are in
Figure S1. Error bars denote standard devia-
tions based on three independent experi-
ments each done in triplicate. 3-way
ANOVA was used to compare each variant,
adjusted for theother twovariants, aBonfer-
roni correction was applied to account for
multiple testing. *p< 0.017, **p% 0.0017.PRE2B-REF/REF allele, this time in T-47D cells (MCF-7 FC¼
1.5, p ¼ 0.15; T-47D FC ¼ 2.7, p ¼ 0.002; Figure S5A).
The PRE2DEL-ALT/ALT construct comprises a haplotype
of three tightly linked variants: the ALT alleles of the two
SNPs (rs199804270:GA:G, rs72951831:G:T) with the ALT
(deletion) allele of the structural variant (esv3594306)
that brings two separate ERa, FOXA1, GATA3, and P300
ChIP-seq peaks into juxtaposition (Figure 1B). To differen-
tiate individual effects, each allele of each SNP was
introduced onto esv3594306 insertion and deletion back-
grounds separately using site-directed mutagenesis. The
PRE2A SNP (rs572022984) was not considered further due
to technical issues (Material and methods). In a combined
analysis, adjusting each variant for the other two variants,
there was evidence that deletion constructs consistently
showed greater activity than insertion constructs (MCF-7:
DEL FC ¼ 43.4, INS FC ¼ 34.4, i.e., average additional
FC for DEL ¼ 1.3, phet ¼ 0.01; T-47D: DEL FC ¼ 47.3, INS
FC ¼ 21.6, i.e., average additional FC for DEL ¼ 2.2, phet ¼
1.7 3 108; Figure 3).
CRISPR-based perturbation of PRE2
Reporter gene assays do not reflect the ‘‘normal’’ genomic
context of a regulatory element. Specifically, the assay tests
whether the putative regulatory element can influence
expression in an episomal context21 and from a distance
of a few kilobases; in vivo, PRE2 maps approximately 400
kb from the IGFBP5 promoter. To determine whether
PRE2 acts as an enhancer element in a cellular context,
we used a systematic CRISPR-based enhancer perturbation
approach. We hypothesized that if PRE2 acts as an
enhancer in vivo, targeting a catalytically inactive Cas9
(dCas9) fused to a repressive (KRAB) domain to regions
within PRE2 would result in lower levels of expression of
IGFBP5 (CRISPR interference; CRISPRi); by contrast, target-
ing dCas9 fused to an activating VPR domain would result
in higher levels of expression of IGFBP5 (CRISPR activa-
tion; CRISPRa).22,23 We designed CRISPR single-guide (sg)
RNAs to the ERa ChIP-seq peak at the centromeric break-
point of the deletion (guides PRE2-1 and -2), within the1198 The American Journal of Human Genetics 108, 1190–1203, Julyesv3594306 deletion region (guides PRE2-3 to -6) and to
the ERa ChIP-seq peak at the telomeric breakpoint of the
deletion (guides PRE2-7 to -9; Figure 1B). As positive con-
trols we designed sgRNAs to target the IGFBP5 promoter
(guides PROM-1 to -3; Figure S6A) and the previously char-
acterized causal variant (rs4442975, guide PRE1-1;
Figure S6B). As negative controls we designed sgRNAs to
the published genome-wide association study signal 1 tag
SNP (rs13387042, guides TAG-1 and -2; Figure S6B). We
used MCF-7 cell lines engineered to stably express (1)
dCas9 with a repressive KRAB domain and (2) dCas9
with an activating VPR domain; as an additional control
we used MCF-7 cells that expressed dCas9 without the
KRAB or VPR domains.
In the dCas9 cell line, there was just one sgRNA (PROM-2)
that influenced IGFBP5 expression; this sgRNA targets the
IGFBP5 promoter, colocalizing with the transcription start
site (TSS) and likely reduces expression of IGFBP5 by steric
hindrance (60% reduction, p ¼ 0.004; Figure S7A). In the
CRISPRi setting, all three sgRNAs targeting the IGFBP5
promoter repressed IGFBP5 expression significantly to
8%–15% of levels in the negative controls (p ¼ 0.001, p ¼
0.001, and p¼ 0.0008 for guides PROM-1, -2, and -3, respec-
tively; Figure S8A). No sgRNA targeting non-promoter se-
quences influenced IGFBP5 expression (Figures S8A and
S8B). In theCRISPRa setting, the sgRNA50 to the IGFBP5pro-
moter (PROM-3; Figure 4A) enhanced IGFBP5 expression
more than60-fold (p¼ 0.00008) and the PRE-1-positive con-
trol sgRNA (PRE1-1) targeting rs442975 also enhanced
IGFBP5 expression (FC¼ 3.7, p¼ 0.006; Figure 4A). In addi-
tion, four of the nine sgRNAs targeting sequences at PRE2
enhanced IGFBP5 expression; specifically PRE2-1 and -2 tar-
geting the ERa ChIP-seq peak at the centromeric deletion
breakpoint (PRE2-1: FC ¼ 3.7, p ¼ 0.0005; PRE2-2: FC ¼
3.1,p¼0.001), PRE2-5 at thedistal endof thedeletion region
(PRE2-5: FC¼ 3.2, p¼ 0.002), and PRE2-8 targeting the ERa
ChIP-seq peak immediately telomeric to the deletion region
(PRE2-8: FC¼ 5.3, p¼ 0.002; Figures 4B and5A).Noneof the
sgRNAs influenced expression of two genes mapping imme-




Figure 4. Systematic CRISPRa analysis of
2q35 putative regulatory elements
MCF-7 cells expressing dCas9-VPR were
transduced with CRISPR sgRNAs targeting:
(A) the PRE1 tag SNP rs13387042 (negative
control), the IGFBP5 promoter and the
PRE1 causal variant rs4442975 (positive
control), and (B and C) a series of sites
mapping across PRE2 (Figure 1B). Relative
gene expression (compared to vector
alone) was calculated using the DDCT
method. Full details of guide RNAs are
listed in Table S3. Error bars denote stan-
dard deviations based on three indepen-
dent experiments each done in triplicate.
p values were determined by t tests and a
Bonferroni correction was applied to ac-
count for multiple testing; (A) *p <
0.017, **p < 0.0017, ***p < 0.00017; (B
and C) *p < 0.0056, **p % 0.00056.Discussion
Fine-scale mapping at the 2q35 breast cancer locus in
women of European ancestry3 confirmed rs4442975 as
the probable causal variant at signal 1 and reduced the
number of credible causal variants at signal 2 from 14 to
5;3,14 at signal 3, however, there remained 42 credible
causal variants that could not be excluded as causal on sta-
tistical grounds alone in either the European or the Asian
data. Low-throughput functional approaches that are
used to investigate putative causal variants, including re-
porter gene assays and CRISPR screens, become prohibitive
with large numbers of credible causal variants and most
single locus11,14,24–38 and global3,6 annotation studies
have used co-localization of credible causal variants with
markers of open chromatin, active histone modifications,
and transcription factor binding in relevant cell types toThe American Journal of Human Geprioritize credible causal variants for
functional follow up. Of the 811
annotation tracks that were exam-
ined in a recent global fine-scale map-
ping analysis,3 credible causal vari-
ants were enriched at three types of
genomic features that are relevant to
long-range regulatory elements: (1)
open chromatin in ERþ cell lines
and normal breast, (2) the active his-
tone marks H3K4me1 and H3K27ac
in MCF-7 cells, and (3) ESR1,
FOXA1, GATA3, and P300 TF binding
sites. By aligning the five credible
causal variants at PRE2 and the 42
credible causal variants at PRE3 with
these marks (Table S4), we were able
to prioritize 4 of the 5 credible causal
variants at PRE2 and 2 of the 42 cred-
ible causal variants at PRE3 for follow-
up studies. By taking this approachthere is, inevitably, the possibility that we have excluded
one or more causal variants from our follow-up analyses.
For PRE2 this seems unlikely as we selected four out of
the five credible causal variants for further follow-up
studies. For PRE3 it is entirely possible, or even probable,
that we failed to prioritize one or more causal variant(s);
improving our ability to discriminate more accurately be-
tween potentially functional variants and large numbers
of correlated variants will require genome-wide datasets
with functional outputs21,39,40 generated in more relevant
cellular disease models and taking advantage of single-cell
technologies.1
Using reporter gene assays, we have demonstrated that
both the distal region of PRE2 (PRE2B) and the entire
PRE3 region can enhance transcription from the IGFBP5
promoter in a cell-type-specific manner. Despite co-local-
izing with multiple markers, we found no evidence thatnetics 108, 1190–1203, July 1, 2021 1199
A
B
Figure 5. Increasing the local density of
activator TF domains with dCas9-VPR or
by juxtaposition of two ChIP-seq peaks is
associated with increased expression of
IGFBP5
(A) Introducing dCas9 fused to a VPR acti-
vator domain at the ERa, FOXA1, GATA3
ChIP-seq peak at the centromeric end of
the deletion breakpoint (PRE2-1 and
PRE2-2), proximal to, or at, the ERa,
FOXA1, GATA3 ChIP-seq peak at the telo-
meric end of the deletion breakpoint
(PRE2-5 and PRE2-8, respectively) in-
creases expression of IGFBP5 in MCF-7
cells.
(B) Deletion of 1.4 kb on the ALT allele of
esv3594306 juxtaposes these two ERa,
FOXA1, GATA3 ChIP-seq peaks.
In each case (A and B) this increases the
density of activating TF domains in the re-
gion and is associated with increased
expression of IGFBP5.the proximal region of PRE2 (PRE2A) acts as an indepen-
dent enhancer element. The ChIP-seq peaks at this region
are, however, relatively weak (Figure 1B); combining data
from both PRE2A alleles, in both breast cancer cell lines
to increase our power (i.e., using 12 replicates rather than
3) the overall mean fold change for PRE2A was 1.14
(1.03–1.26, p ¼ 0.01), consistent with the presence of a
very modest enhancer element. Comparing REF constructs
with ALT constructs, we found no evidence that either of
the credible causal variants at PRE3 (rs12694417,
rs12988242) altered the activity of the PRE. This does not
exclude these SNPs as functional; as above, modest effects
on enhancer activitymay be difficult to detect and variants
that, for example, influence chromatin accessibility may
not be detectable in transient assays.11 However, without
preliminary in vitro evidence to suggest that one of these
variants alters cell-type-specific transcription from the
IGFBP5 promoter, pursuing further functional studies
that are predicated on this very assumption seems unlikely1200 The American Journal of Human Genetics 108, 1190–1203, July 1, 2021to be fruitful. By contrast, one com-
parison that was consistent and sig-
nificant between constructs and
across the two breast cancer cell lines
was that PRE2 deletion alleles had
stronger enhancer activity than
PRE2 insertion alleles.
The purpose of our CRISPR-based
enhancer perturbation was 2-fold:
specifically, to interrogate the PRE2 re-
gion within its normal genomic
context andmoregenerally toevaluate
CRISPRi and CRISPRa approaches for
interrogating long-range regulatory el-
ements that harbor credible causal var-
iants. As none of our PRE2 sgRNAs
impacted IGFBP5 expression signifi-cantly in the CRISPRi setting, our analysis raises questions
as to the utility of this approach for characterizing long-
range regulatory elements (PRE2 maps approximately 400
kb telomeric to the IGFBP5promoter). This is atoddswith re-
sults of a systematic CRISPRi screen to identify enhancer
elements in K562 cells, which demonstrated CRISPRi-medi-
ated repression of c-MYCexpression by sgRNAs targeting se-
quences mapping up to 1.9 Mb downstream of c-MYC.22 In
this analysis, however, CRISPRi-mediated repression by
these distal elements was modest compared to CRISPRi-
mediated repression by more proximal elements and, even
based on12 biological replicates, of borderline statistical sig-
nificance.22 By contrast, using CRISPRa we were able to
confirm that one or more elements within PRE2 can act as
a long-range regulatory element that specifically targets
IGFBP5 (rather than IGFBP2 or RPL37A). Four of the nine
guide RNAs targeting dCas9-VPR to sequences at PRE2
increased expression of IGFBP5; three of these colocalized
with ERa, FOXA1, and GATA3 ChIP-seq peaks (PRE2-1, -2,
and -8) and a fourth (PRE2-5) mapped within the
esv3594306 deleted region (Figure 5A). There were also
two guides which targeted dCas9-VPR to sequences that
map close to the distal ERa, FOXA1, and GATA3 ChIP-seq
peak (PRE2-6and -7)butdidnot increase IGFBP5 expression;
thismay reflect the very variable efficiencyof different guide
RNAs.22 We present a theoretical model in which we hy-
pothesize that all of the PRE2 guides that increased expres-
sion of IGFBP5 increased the local density of activating TF
domains by bringing a VPR domain into the proximity of
a cluster of TF ChIP-seq peaks; one implication of the in-
crease in IGFBP5expressionweobservedwithPRE2-5,which
maps approximately 450 bp from the center of the nearest
cluster of ChIP-seq peaks (Figure 5A), is that these regulatory
elements may extend over relatively large (>1 kb) regions.
This should not, perhaps, be surprising; at a subset of
strongly activated E2-responsive enhancers, it has previ-
ously been shown that ERa recruits DNA-binding transcrip-
tion factors in trans, to form a large (1–2 MDa) complex.41
It has previously been suggested that sequences map-
ping to PRE2 act as a repressor element which, in the pres-
ence of low-dose estradiol, acts to reduce IGFBP5 expres-
sion.14 By contrast, our data support PRE2 acting as a
powerful enhancer element with the deletion allele
increasing expression of IGFBP5 over and above that of
the insertion allele with or without estradiol stimulation.
Overall, our data are consistent with a hypothetical model
in which the juxtaposition of the two ERa, FOXA1, GATA3
binding sites at PRE2 by deletion of approximately 1.4 kb
of intervening sequence generates a single extended bind-
ing region (Figure 5B) that is causally associated with
increased enhancer activity, higher levels of expression of
the putative tumor suppressor gene IGFBP5,42 and a reduc-
tion in breast cancer risk (OR ¼ 0.77, p ¼ 2.2 3 1029) that
is largely restricted to ERþ disease.
In conclusion, we have identified putative enhancer ele-
ments at two additional 2q35 breast cancer risk loci. One of
these, mapping approximately 400 kb telomeric to IGFBP5,
enhances transcription from the IGFBP5 promoter by a fac-
tor of 30- to 40-fold. For this element we provide evidence
that a deletion of 1.4 kb is causally associated with
increased enhancer activity and suggest a mechanism for
this increased activity.Data and code availability
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